Paul Phillips
Concepts (281)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diplopia | 8 | 2024 | 19 | 2.430 |
Why?
| Exotropia | 7 | 2023 | 9 | 2.140 |
Why?
| Oculomotor Muscles | 5 | 2019 | 23 | 2.010 |
Why?
| Pseudotumor Cerebri | 7 | 2024 | 26 | 2.000 |
Why?
| Ocular Motility Disorders | 5 | 2018 | 17 | 1.960 |
Why?
| Ophthalmologic Surgical Procedures | 4 | 2019 | 22 | 1.880 |
Why?
| Vision, Low | 3 | 2022 | 9 | 1.710 |
Why?
| Optic Nerve | 6 | 2014 | 50 | 1.670 |
Why?
| Papilledema | 5 | 2022 | 27 | 1.480 |
Why?
| Optic Disk | 2 | 2023 | 21 | 1.410 |
Why?
| Intracranial Pressure | 5 | 2019 | 29 | 1.390 |
Why?
| Magnetic Resonance Imaging | 15 | 2023 | 1556 | 1.310 |
Why?
| Hypopituitarism | 4 | 2014 | 17 | 1.240 |
Why?
| Eye Abnormalities | 4 | 2023 | 24 | 1.200 |
Why?
| Strabismus | 5 | 2019 | 14 | 1.130 |
Why?
| Child | 31 | 2024 | 6910 | 1.090 |
Why?
| Ophthalmology | 2 | 2023 | 32 | 1.040 |
Why?
| Intracranial Hypertension | 3 | 2019 | 31 | 1.020 |
Why?
| Pituitary Gland | 3 | 2014 | 85 | 1.020 |
Why?
| Vision, Binocular | 4 | 2019 | 6 | 0.990 |
Why?
| Oculomotor Nerve Diseases | 2 | 2017 | 5 | 0.960 |
Why?
| Optic Nerve Diseases | 3 | 2023 | 22 | 0.950 |
Why?
| Humans | 68 | 2024 | 50516 | 0.870 |
Why?
| Vision Screening | 1 | 2022 | 10 | 0.810 |
Why?
| Fixation, Ocular | 3 | 2019 | 12 | 0.800 |
Why?
| Abducens Nerve Diseases | 2 | 2024 | 7 | 0.790 |
Why?
| Eye Diseases, Hereditary | 2 | 2017 | 5 | 0.750 |
Why?
| Tomography, Optical Coherence | 5 | 2022 | 107 | 0.730 |
Why?
| Dyslexia | 2 | 2018 | 55 | 0.700 |
Why?
| Distance Perception | 1 | 2019 | 3 | 0.670 |
Why?
| Postoperative Complications | 3 | 2015 | 1033 | 0.630 |
Why?
| Child, Preschool | 20 | 2024 | 3943 | 0.620 |
Why?
| Orthoptics | 1 | 2018 | 1 | 0.610 |
Why?
| Male | 36 | 2024 | 25913 | 0.600 |
Why?
| Vision Disorders | 3 | 2024 | 59 | 0.560 |
Why?
| Visual Acuity | 9 | 2022 | 144 | 0.550 |
Why?
| Apraxias | 3 | 2013 | 9 | 0.540 |
Why?
| Cavernous Sinus | 2 | 2011 | 16 | 0.540 |
Why?
| Female | 34 | 2024 | 27086 | 0.530 |
Why?
| Retinal Hemorrhage | 3 | 2023 | 14 | 0.510 |
Why?
| Eyeglasses | 3 | 2023 | 9 | 0.500 |
Why?
| Adolescent | 14 | 2024 | 6446 | 0.490 |
Why?
| Diagnosis, Differential | 9 | 2018 | 1033 | 0.480 |
Why?
| Nervous System Diseases | 2 | 2005 | 89 | 0.460 |
Why?
| Blindness | 3 | 2024 | 31 | 0.450 |
Why?
| Infant | 12 | 2024 | 3629 | 0.410 |
Why?
| Comprehension | 2 | 2024 | 116 | 0.410 |
Why?
| Developmental Disabilities | 2 | 2013 | 120 | 0.410 |
Why?
| Meningitis, Cryptococcal | 1 | 2012 | 10 | 0.400 |
Why?
| Blepharoptosis | 1 | 2012 | 13 | 0.390 |
Why?
| Cryptococcus neoformans | 1 | 2012 | 27 | 0.390 |
Why?
| Retinal Diseases | 2 | 2024 | 51 | 0.380 |
Why?
| Internet | 2 | 2024 | 259 | 0.380 |
Why?
| Carotid Artery, Internal, Dissection | 1 | 2011 | 8 | 0.380 |
Why?
| Brain Diseases | 2 | 2012 | 83 | 0.370 |
Why?
| Tuberous Sclerosis | 1 | 2011 | 37 | 0.360 |
Why?
| Intracranial Aneurysm | 1 | 2011 | 47 | 0.360 |
Why?
| Retrospective Studies | 11 | 2024 | 6264 | 0.350 |
Why?
| Neurofibromatosis 1 | 1 | 2010 | 32 | 0.350 |
Why?
| Optic Disk Drusen | 1 | 2009 | 3 | 0.320 |
Why?
| Hemianopsia | 1 | 2009 | 5 | 0.320 |
Why?
| United States | 7 | 2024 | 4955 | 0.320 |
Why?
| Cerebrospinal Fluid Shunts | 1 | 2008 | 22 | 0.310 |
Why?
| Dyskeratosis Congenita | 1 | 2008 | 2 | 0.300 |
Why?
| Cerebellum | 2 | 2013 | 131 | 0.300 |
Why?
| Rhombencephalon | 1 | 2007 | 4 | 0.300 |
Why?
| Adrenoleukodystrophy | 1 | 2007 | 1 | 0.290 |
Why?
| Botulinum Toxins | 1 | 2007 | 5 | 0.290 |
Why?
| Membrane Proteins | 2 | 2024 | 332 | 0.280 |
Why?
| Visual Pathways | 2 | 2023 | 10 | 0.260 |
Why?
| Cross-Sectional Studies | 6 | 2024 | 1608 | 0.250 |
Why?
| Fluorescein Angiography | 2 | 2022 | 34 | 0.250 |
Why?
| Aged | 8 | 2024 | 9743 | 0.240 |
Why?
| Muscarinic Agonists | 1 | 2024 | 11 | 0.240 |
Why?
| Craniocerebral Trauma | 2 | 2023 | 66 | 0.240 |
Why?
| Pilocarpine | 1 | 2024 | 25 | 0.230 |
Why?
| Cerebrospinal Fluid Pressure | 2 | 2016 | 3 | 0.230 |
Why?
| Aqueous Humor | 1 | 2024 | 10 | 0.230 |
Why?
| Retinal Artery Occlusion | 1 | 2024 | 13 | 0.230 |
Why?
| Retinal Detachment | 1 | 2024 | 26 | 0.230 |
Why?
| Eye Diseases | 1 | 2024 | 34 | 0.230 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.230 |
Why?
| Consumer Health Information | 1 | 2024 | 18 | 0.230 |
Why?
| Patient Education as Topic | 2 | 2024 | 320 | 0.220 |
Why?
| Follow-Up Studies | 5 | 2024 | 2242 | 0.220 |
Why?
| Middle Aged | 8 | 2024 | 12613 | 0.220 |
Why?
| Adult | 11 | 2024 | 13584 | 0.220 |
Why?
| Eye Injuries | 1 | 2024 | 25 | 0.220 |
Why?
| Retirement | 1 | 2023 | 16 | 0.220 |
Why?
| Diabetic Retinopathy | 1 | 2024 | 44 | 0.210 |
Why?
| Optic Chiasm | 1 | 2003 | 9 | 0.210 |
Why?
| Optic Atrophy, Hereditary, Leber | 1 | 2003 | 4 | 0.210 |
Why?
| Self Report | 1 | 2024 | 206 | 0.210 |
Why?
| Patient Selection | 1 | 2024 | 259 | 0.210 |
Why?
| Dementia | 1 | 2024 | 148 | 0.210 |
Why?
| Young Adult | 5 | 2019 | 4107 | 0.200 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 14 | 0.200 |
Why?
| Forecasting | 1 | 2023 | 147 | 0.200 |
Why?
| Meningeal Neoplasms | 1 | 2023 | 52 | 0.200 |
Why?
| Central Nervous System Neoplasms | 1 | 2023 | 63 | 0.200 |
Why?
| Charcot-Marie-Tooth Disease | 1 | 2022 | 8 | 0.200 |
Why?
| Optic Atrophy | 1 | 2022 | 16 | 0.190 |
Why?
| Anesthetics, Combined | 1 | 2001 | 2 | 0.190 |
Why?
| Anesthesia, Local | 1 | 2001 | 16 | 0.190 |
Why?
| Proteomics | 1 | 2024 | 314 | 0.190 |
Why?
| Brain Injuries | 1 | 2023 | 159 | 0.190 |
Why?
| Ophthalmoscopy | 2 | 2013 | 14 | 0.190 |
Why?
| Giant Cell Arteritis | 1 | 2021 | 12 | 0.190 |
Why?
| Prospective Studies | 4 | 2019 | 2378 | 0.190 |
Why?
| Child Abuse | 1 | 2023 | 136 | 0.180 |
Why?
| Macular Degeneration | 1 | 2021 | 27 | 0.180 |
Why?
| Orbital Diseases | 1 | 2001 | 14 | 0.180 |
Why?
| Vision Tests | 3 | 2023 | 13 | 0.180 |
Why?
| Phacoemulsification | 1 | 2001 | 35 | 0.180 |
Why?
| Anesthetics, Local | 1 | 2001 | 76 | 0.180 |
Why?
| Choroiditis | 1 | 2020 | 9 | 0.180 |
Why?
| Multiple Sclerosis | 1 | 2021 | 65 | 0.180 |
Why?
| Socioeconomic Factors | 1 | 2023 | 591 | 0.180 |
Why?
| Health Status Disparities | 1 | 2023 | 202 | 0.170 |
Why?
| Mutation | 3 | 2017 | 1281 | 0.170 |
Why?
| Reproducibility of Results | 3 | 2024 | 1199 | 0.170 |
Why?
| Vitreoretinal Surgery | 1 | 2019 | 8 | 0.170 |
Why?
| Crohn Disease | 1 | 2020 | 93 | 0.160 |
Why?
| Carotid Artery Diseases | 1 | 1999 | 33 | 0.160 |
Why?
| Arteriovenous Fistula | 1 | 1999 | 30 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2023 | 281 | 0.160 |
Why?
| Prevalence | 1 | 2022 | 971 | 0.160 |
Why?
| Aged, 80 and over | 3 | 2024 | 3227 | 0.160 |
Why?
| Laser Therapy | 1 | 2019 | 83 | 0.160 |
Why?
| Sensitivity and Specificity | 2 | 2013 | 861 | 0.160 |
Why?
| Retina | 2 | 2024 | 63 | 0.160 |
Why?
| Astigmatism | 1 | 2018 | 5 | 0.150 |
Why?
| Amblyopia | 1 | 2018 | 4 | 0.150 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 151 | 0.150 |
Why?
| Mydriatics | 1 | 2018 | 12 | 0.150 |
Why?
| Pupil | 1 | 2018 | 29 | 0.150 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2018 | 16 | 0.150 |
Why?
| Obesity | 3 | 2016 | 1121 | 0.150 |
Why?
| Convergence, Ocular | 1 | 2017 | 2 | 0.150 |
Why?
| Accommodation, Ocular | 1 | 2017 | 3 | 0.140 |
Why?
| Glucose Transport Proteins, Facilitative | 1 | 2017 | 9 | 0.140 |
Why?
| Myopia | 1 | 2017 | 9 | 0.140 |
Why?
| Keratoconus | 1 | 2017 | 4 | 0.140 |
Why?
| Reading | 1 | 2018 | 85 | 0.140 |
Why?
| Skin Diseases, Genetic | 1 | 2017 | 8 | 0.140 |
Why?
| Heterozygote | 1 | 2017 | 83 | 0.140 |
Why?
| Minocycline | 1 | 2017 | 14 | 0.140 |
Why?
| Cornea | 1 | 2017 | 51 | 0.140 |
Why?
| Subarachnoid Hemorrhage | 1 | 2018 | 65 | 0.140 |
Why?
| Joint Instability | 1 | 2017 | 40 | 0.140 |
Why?
| Arteries | 1 | 2017 | 91 | 0.140 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2016 | 6 | 0.140 |
Why?
| Syndrome | 1 | 2017 | 240 | 0.130 |
Why?
| Acetazolamide | 1 | 2016 | 19 | 0.130 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 172 | 0.130 |
Why?
| Depth Perception | 2 | 2005 | 4 | 0.130 |
Why?
| Risk Factors | 3 | 2024 | 3723 | 0.120 |
Why?
| Vascular Malformations | 1 | 2017 | 102 | 0.120 |
Why?
| Chi-Square Distribution | 2 | 2005 | 277 | 0.120 |
Why?
| Nevus of Ota | 1 | 2014 | 2 | 0.120 |
Why?
| Scleral Diseases | 1 | 2014 | 2 | 0.120 |
Why?
| Eye Neoplasms | 1 | 2014 | 9 | 0.120 |
Why?
| Siblings | 1 | 2014 | 33 | 0.120 |
Why?
| Functional Laterality | 1 | 2014 | 89 | 0.120 |
Why?
| Sex Factors | 2 | 2016 | 711 | 0.110 |
Why?
| Treatment Outcome | 3 | 2019 | 5285 | 0.110 |
Why?
| Cogan Syndrome | 1 | 2013 | 2 | 0.110 |
Why?
| Kidney Diseases, Cystic | 1 | 2013 | 19 | 0.110 |
Why?
| Cerebellar Diseases | 1 | 2013 | 17 | 0.110 |
Why?
| Body Mass Index | 1 | 2016 | 677 | 0.110 |
Why?
| Optic Nerve Neoplasms | 2 | 2004 | 7 | 0.100 |
Why?
| Stroke | 1 | 2018 | 495 | 0.100 |
Why?
| Case-Control Studies | 2 | 2005 | 1155 | 0.100 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 198 | 0.100 |
Why?
| Myasthenia Gravis | 1 | 2012 | 17 | 0.100 |
Why?
| Visual Fields | 2 | 2009 | 39 | 0.100 |
Why?
| Orbit | 2 | 2003 | 27 | 0.100 |
Why?
| Risk Assessment | 1 | 2016 | 1269 | 0.100 |
Why?
| Anti-Bacterial Agents | 1 | 2017 | 745 | 0.090 |
Why?
| Sex Distribution | 2 | 2024 | 136 | 0.090 |
Why?
| Acute Disease | 2 | 2021 | 373 | 0.090 |
Why?
| Optic Nerve Injuries | 1 | 2009 | 7 | 0.080 |
Why?
| Skin Neoplasms | 1 | 2014 | 491 | 0.080 |
Why?
| Paranasal Sinuses | 1 | 2009 | 16 | 0.080 |
Why?
| Decompression, Surgical | 1 | 2009 | 49 | 0.080 |
Why?
| Equipment Failure | 1 | 2008 | 63 | 0.080 |
Why?
| Hydrocephalus | 1 | 2008 | 43 | 0.080 |
Why?
| Endoscopy | 1 | 2009 | 119 | 0.070 |
Why?
| Blood Transfusion | 1 | 2008 | 129 | 0.070 |
Why?
| Tomography, X-Ray Computed | 2 | 2009 | 1169 | 0.070 |
Why?
| DNA, Mitochondrial | 2 | 2003 | 111 | 0.060 |
Why?
| Ophthalmic Solutions | 1 | 2024 | 19 | 0.060 |
Why?
| Age Factors | 2 | 2019 | 1110 | 0.060 |
Why?
| Administration, Topical | 1 | 2024 | 57 | 0.060 |
Why?
| Phosphopyruvate Hydratase | 1 | 2024 | 10 | 0.060 |
Why?
| Prognosis | 1 | 2010 | 1977 | 0.060 |
Why?
| Vitreous Body | 1 | 2024 | 20 | 0.060 |
Why?
| Bone Diseases, Developmental | 1 | 2024 | 14 | 0.060 |
Why?
| Paracentesis | 1 | 2024 | 13 | 0.060 |
Why?
| Eye Proteins | 1 | 2024 | 17 | 0.060 |
Why?
| Methylprednisolone | 2 | 2018 | 39 | 0.060 |
Why?
| Neuronal Ceroid-Lipofuscinoses | 1 | 2004 | 6 | 0.060 |
Why?
| Chromosomes, Human, Pair 15 | 1 | 2004 | 9 | 0.060 |
Why?
| Retinal Degeneration | 1 | 2004 | 10 | 0.060 |
Why?
| Propensity Score | 1 | 2024 | 136 | 0.060 |
Why?
| Vitrectomy | 1 | 2024 | 59 | 0.050 |
Why?
| Refraction, Ocular | 1 | 2023 | 7 | 0.050 |
Why?
| Exons | 1 | 2004 | 93 | 0.050 |
Why?
| Molecular Chaperones | 1 | 2004 | 61 | 0.050 |
Why?
| Cultural Diversity | 1 | 2023 | 37 | 0.050 |
Why?
| Optic Atrophies, Hereditary | 1 | 2003 | 2 | 0.050 |
Why?
| Hematoma, Subdural | 1 | 2023 | 21 | 0.050 |
Why?
| Schools, Medical | 1 | 2023 | 70 | 0.050 |
Why?
| Hypertrophy | 1 | 2003 | 50 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2004 | 134 | 0.050 |
Why?
| Ischemia | 1 | 2024 | 153 | 0.050 |
Why?
| Mass Spectrometry | 1 | 2024 | 285 | 0.050 |
Why?
| Biopsy | 2 | 2021 | 588 | 0.050 |
Why?
| Faculty, Medical | 1 | 2023 | 92 | 0.050 |
Why?
| DNA Mutational Analysis | 1 | 2003 | 175 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 245 | 0.050 |
Why?
| Electronic Health Records | 1 | 2024 | 220 | 0.050 |
Why?
| Health Literacy | 1 | 2024 | 129 | 0.050 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 153 | 0.050 |
Why?
| Needlestick Injuries | 1 | 2001 | 2 | 0.050 |
Why?
| Pituitary Hormones | 1 | 2001 | 18 | 0.050 |
Why?
| Vaccination | 1 | 2024 | 280 | 0.050 |
Why?
| Scotoma | 1 | 2021 | 7 | 0.050 |
Why?
| Lens Implantation, Intraocular | 1 | 2001 | 24 | 0.050 |
Why?
| Spinal Puncture | 2 | 2018 | 17 | 0.050 |
Why?
| Fundus Oculi | 1 | 2021 | 25 | 0.050 |
Why?
| Temporal Arteries | 1 | 2021 | 15 | 0.050 |
Why?
| Bupivacaine | 1 | 2001 | 28 | 0.050 |
Why?
| Incidence | 1 | 2024 | 1032 | 0.050 |
Why?
| Lidocaine | 1 | 2001 | 48 | 0.050 |
Why?
| Macrophages | 1 | 2024 | 364 | 0.050 |
Why?
| Mucormycosis | 1 | 2001 | 27 | 0.050 |
Why?
| Graves Disease | 1 | 2001 | 19 | 0.050 |
Why?
| Pilot Projects | 1 | 2023 | 699 | 0.040 |
Why?
| Eye Infections, Fungal | 1 | 2001 | 19 | 0.040 |
Why?
| Intravitreal Injections | 1 | 2020 | 33 | 0.040 |
Why?
| Saccades | 1 | 2000 | 4 | 0.040 |
Why?
| Pedigree | 1 | 2000 | 119 | 0.040 |
Why?
| Aspergillosis | 1 | 2001 | 124 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 484 | 0.040 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 182 | 0.040 |
Why?
| Angiogenesis Inhibitors | 1 | 2020 | 183 | 0.040 |
Why?
| Trochlear Nerve | 1 | 1999 | 1 | 0.040 |
Why?
| Ophthalmoplegia | 1 | 1999 | 6 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 562 | 0.040 |
Why?
| Postoperative Care | 1 | 2019 | 104 | 0.040 |
Why?
| Cranial Nerve Diseases | 1 | 1999 | 15 | 0.040 |
Why?
| Refractive Errors | 1 | 2018 | 5 | 0.040 |
Why?
| Tropicamide | 1 | 2018 | 5 | 0.040 |
Why?
| Cyclopentolate | 1 | 2018 | 5 | 0.040 |
Why?
| Equipment Design | 1 | 2019 | 289 | 0.040 |
Why?
| Phenylephrine | 1 | 2018 | 34 | 0.040 |
Why?
| Drug Combinations | 1 | 2018 | 127 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2004 | 600 | 0.040 |
Why?
| Phlebography | 1 | 2018 | 60 | 0.040 |
Why?
| Corneal Topography | 1 | 2017 | 6 | 0.040 |
Why?
| Corneal Pachymetry | 1 | 2017 | 5 | 0.040 |
Why?
| Dilatation, Pathologic | 1 | 2017 | 24 | 0.040 |
Why?
| Sexual Maturation | 1 | 2016 | 14 | 0.030 |
Why?
| Age Distribution | 1 | 2016 | 170 | 0.030 |
Why?
| Morbidity | 1 | 2016 | 130 | 0.030 |
Why?
| Glucocorticoids | 1 | 2018 | 230 | 0.030 |
Why?
| Disease Progression | 1 | 2018 | 829 | 0.030 |
Why?
| Cytoskeletal Proteins | 1 | 2013 | 47 | 0.030 |
Why?
| Abnormalities, Multiple | 1 | 2013 | 167 | 0.020 |
Why?
| Recovery of Function | 1 | 2009 | 191 | 0.020 |
Why?
| Brain | 2 | 2004 | 1323 | 0.020 |
Why?
| Electroretinography | 1 | 2004 | 17 | 0.010 |
Why?
| Microscopy, Electron | 1 | 2004 | 77 | 0.010 |
Why?
| Neurologic Examination | 1 | 2004 | 76 | 0.010 |
Why?
| Alleles | 1 | 2004 | 255 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 449 | 0.010 |
Why?
| Electroencephalography | 1 | 2004 | 308 | 0.010 |
Why?
| Hemorrhage | 1 | 2003 | 197 | 0.010 |
Why?
| Skin | 1 | 2004 | 389 | 0.010 |
Why?
| Muscle, Skeletal | 1 | 2004 | 784 | 0.010 |
Why?
|
|
Phillips's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|